For instance, BRAF inhibitors like vemurafenib or dabrafenib can be used to target BRAF V600E mutations in pleomorphic xanthoastrocytomas and gangliogliomas, frequently leading to significant tumor regression. Here, BRAF is linked to neoplasm.